Items where authors include "Pratt, G"

Export as [feed] Atom [feed] RSS
Number of items: 17.

Article

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

Giles, HV, Cook, MA, Drayson, MT et al. (12 more authors) (2021) Redefining Non-measurable Multiple Myeloma Using Mass Spectrometry. Blood. ISSN 0006-4971

Rana, R, Cockwell, P, Drayson, M et al. (8 more authors) (2020) Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Advances, 4 (22). pp. 5836-5845. ISSN 2473-9529

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Pratt, G et al. (13 more authors) (2020) Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy. British Journal of Haematology. ISSN 0007-1048

Drayson, MT, Bowcock, S, Planche, T et al. (23 more authors) (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet Oncology, 20 (12). pp. 1760-1772. ISSN 1470-2045

Drayson, MT, Bowcock, S, Planche, T et al. (13 more authors) (2019) Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23 (62). pp. 1-94. ISSN 1366-5278

Ahmedzai, SH, Snowden, JA, Ashcroft, AJ et al. (19 more authors) (2019) Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. Journal of Clinical Oncology, 37 (19). pp. 1617-1628. ISSN 0732-183X

Cook, G, Royle, K-L, O'Connor, S et al. (20 more authors) (2019) The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. British Journal of Haematology, 185 (3). pp. 450-467. ISSN 0007-1048

Went, M, Sud, A, Speedy, H et al. (52 more authors) (2018) Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer Journal, 9. ARTN 1. ISSN 2044-5385

Chapman, MA, Sive, J, Ambrose, J et al. (27 more authors) (2018) RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood, 132 (20). pp. 2154-2165. ISSN 0006-4971

Agathanggelou, A, Smith, E, Davies, NJ et al. (20 more authors) (2017) USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. Blood, 130 (2). pp. 156-166. ISSN 0006-4971

Jones, JR, Cairns, DA, Gregory, WM orcid.org/0000-0003-2641-8416 et al. (19 more authors) (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 6 (12). e506. ISSN 2044-5385

Maybury, B, Cook, G, Pratt, G et al. (2 more authors) (2016) Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. Biology of Blood and Marrow Transplantation, 22 (11). pp. 1926-1937. ISSN 1083-8791

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (16 more authors) (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. The Lancet Haematology, 3 (7). e340-e351.

Kwok, M, Davies, N, Agathanggelou, A et al. (12 more authors) (2016) ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood, 127 (5). pp. 582-595. ISSN 0006-4971

Proceedings Paper

Yong, K, Royle, K-L orcid.org/0000-0003-0225-1199, Ramasamy, K et al. (23 more authors) (2022) Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation. In: Blood. 64th ASH Annual Meeting, 10-13 Dec 2022, New Orleans, Louisiana. American Society of Hematology , pp. 1844-1846.

Sherborne, AL, Shah, V, Ellis, S et al. (15 more authors) (2017) Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. In: Blood. 59th ASH Annual Meeting and Exposition, 09-12 Dec 2017, Atlanta, GA, USA. American Society of Hematology , p. 1767.

This list was generated on Sun Mar 24 13:59:04 2024 GMT.